Clinical Trial Update: Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens [Phase 2]

View source ↗

Summary

A Phase 2 dose-response study of a recombinant Phleum grass pollen allergen cocktail (rPhleum) in Type I allergy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• rPhleum (recombinant Phleum pratense allergen)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Type I-Allergy | Phase 2 | Status: COMPLETED